Clinical trialPhase 2Recruiting
Tamoxifen for Advanced Solid Pseudopapillary Tumor of the Pancreas
- Outcome
- Ongoing
- Phase
- Phase 2
- Status
- Recruiting
- Study type
- Interventional
- Start
- 20 March 2025
- Expected end
- 28 February 2028
- Enrollment
- 30 participants
- Sites
- 1
- Primary outcomes
- Progression-free survival (PFSn)
- Sponsor
- Other
- Results posted
- No
- Last update
- 6 April 2025
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
Tamoxifen for Solid Pseudopapillary Tumor of the Pancreas
Detailed description public domain (ClinicalTrials.gov)
Solid pseudopapillary tumor of the pancreas (SPTP) is a rare neoplasm, predominantly affecting young females, with unclear pathogenesis and hormonal receptor (estrogen/progesterone receptor) expression potentially influencing tumor behavior. While surgical resection is the standard treatment, patients with advanced, metastatic, or recurrent disease lack effective therapies. Case reports suggest tamoxifen, a selective estrogen receptor modulator, may improve outcomes in hormone receptor-positive SPTP. This trial aims to evaluate tamoxifen's efficacy and safety in advanced SPTP.